Academy symposium - Science for Affordable Health Care in the Netherlands

17 April 2013 from 13:00 to 17:45 hrs
Add event:

Affordable health care is a hot topic. The growing number of treatments (both technical and medicinal) and the huge costs that they often impose on society make a review of health care policy a necessity.

Clinical studies required to develop diagnostic techniques or to demonstrate that new treatments are effective (or more effective than existing ones) drive some of this cost. Although it is primarily up to government and society to set upper limits on the cost of a treatment, researchers naturally also bear a share of the responsibility.

How can research focus more on balancing clinical effectiveness against affordability?
The aim of this symposium is to discuss this subject and to explore whether and how clinical research can help control the costs of quality health care.

The symposium is intended for all those involved in health research, in particular clinical and scientific researchers, health economists, associations of patients, behavioural scientists, insurers and pharmaceutical companies. In addition to oncology, the theme covers other fields of medicine, such as pain management, diabetes and arthritis.

The keynote speaker is Richard Sullivan (Kings College London), whose article in The Lancet last year sparked off a lively discussion about the costs and quality of health care.

Language of plenary session: English. Language of workshops and presentation of results: Dutch


1:00 p.m.

Introduction, Jaap Verweij, symposium chairman, Professor of Medical Oncology, Erasmus MC

1:05 p.m.

The Death of Affordable Health Care,
Richard Sullivan, Professor in Cancer Policy and Global Health, Kings College London

1:35 p.m.

Why Does It Cost So Much to Develop Medicines?
Carin Uyl-de Groot, Professor in Evaluation of Health Care, Erasmus University Rotterdam

2:00-2:20 p.m.


2:20 p.m.

Data Dense Effective Drug Development of Prototypes from PBDD to IQDD. Would It Be Cheaper in the Long Run?
Adam Cohen, General Director Centre for Human Drug Research (CHDR) 

2:50 p.m.

Health Care Research for Cost Containment: Getting the Relevant Answers.
Bert Boer, chair of the  Package Advisory Committee,  Health Care Insurance Board (CVZ)

3:20-3:40 p.m. 


3:40-5:00 p.m.

Workshops (in Dutch)

  • What possible models are there for the meaningful development of medicines?
    Carin Uyl-de Groot
  • What meaningful endpoints can be applied and do we have the right criteria?
    Jozien Bensing
  • What is the difference between statistical significance and clinical relevance?
    Jaap Verweij
  • What are the consequences of personalized medicine?
    Liesbeth de Vries

5.00-5:45 p.m.

Plenary presentation of workshop results (in Dutch)

5:45 p.m.

Conclusion and reception

Admission is free.